Cost-effectiveness analysis: Out of touch with clinical reality?

被引：18
作者：
Maetzel, A [1 ]
机构：
[1] Univ Toronto, Div Clin Decis Making, Toronto, ON M5G 2C4, Canada
来源：
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH | 2005年 / 53卷 / 01期
关键词：
D O I：
10.1002/art.20906
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3 / 4
页数：2
相关论文
共 10 条
[1]   Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK [J].
Brennan, A ;
Bansback, N ;
Reynolds, A ;
Conway, P .
RHEUMATOLOGY, 2004, 43 (01) :62-72
[2]   TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden [J].
Kobelt, G ;
Eberhardt, K ;
Geborek, P .
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (01) :4-10
[3]  
LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473
[4]   Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis [J].
Maetzel, A ;
Strand, V ;
Tugwell, P ;
Wells, G ;
Bombardier, C .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2002, 47 (06) :655-661
[5]  
*NAT I CLIN EXC, 2002, GUID US ET INFL TREA
[6]   What is the price of life and why doesn't it increase at the rate of inflation? [J].
Ubel, PA ;
Hirth, RA ;
Chernew, ME ;
Fendrick, AM .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (14) :1637-1641
[7]   Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR task force on good research practices-modeling studies [J].
Weinstein, MC ;
O'Brien, B ;
Hornberger, J ;
Jackson, J ;
Johannesson, M ;
McCabe, C ;
Luce, BR .
VALUE IN HEALTH, 2003, 6 (01) :9-17
[8]   Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands [J].
Welsing, PMJ ;
Severens, JL ;
Hartman, M ;
van Riel, PLCM ;
Laan, RFJM .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2004, 51 (06) :964-973
[9]   Do rheumatology cost-effectiveness analyses make sense? [J].
Wolfe, F ;
Michaud, K ;
Pincus, T .
RHEUMATOLOGY, 2004, 43 (01) :4-6
[10]   Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis [J].
Wong, JB ;
Kavanagh, A .
AMERICAN JOURNAL OF MEDICINE, 2002, 113 (05) :400-408
1